
    
      This study is designed to evaluate the absolute bioavailability, pharmacokinetics,
      tolerability, and safety of a single dose (groups 1-4) or multiple doses (groups 5-6) of
      belimumab administered subcutaneously (SC) to healthy subjects.
    
  